Market Access Agreements for pharmaceuticals in Europe: Diversity of approaches and underlying concepts

BMC Health Services Research

Volumn 11, Issue , 2011, Pages

  Jarosawski, Szymon ^a,b   Toumi, Mondher ^c  

^a CREATIV CEUTICAL   (France)

^b Institute of Bioinformatics and Applied Biotechnology   (India)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COHORT ANALYSIS; COMMERCIAL PHENOMENA; COST CONTROL; DRUG COST; DRUG INDUSTRY; ECONOMICS; EUROPE; HEALTH CARE COST; HUMAN; ORGANIZATION AND MANAGEMENT; REVIEW; STATISTICS;

COHORT STUDIES; COMMERCE; COST CONTROL; DRUG COSTS; DRUG INDUSTRY; EUROPE; HEALTH CARE SECTOR; HUMANS;

EID: 80053585584     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-11-259     Document Type: Review

References (48)

1. Health Systems Institutional Characteristics. OECD, OECD Health Working Papers Paris: OECD 2010 50
2. DIFFERENCES IN COSTS OF AND ACCESS TO PHARMACEUTICAL PRODUCTS IN THE EU. Study. Kanavos P, POLICIES DGFI ed. Brussels,: European Parliament 2011
3. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, et al. BMC Health Serv Res 2010 10 153 10.1186/1472-6963-10-153 20529296
4. Skjult markedsføringsinitiativ. http://taenk.dk/dokumentation/ breve/skjult-markedsf%C3%B8ringsinitiativ
5. Potenspiller: Fuld tilfredshed eller pengene tilbage. http://jp.dk/indland/article237683.ece
6. European Market Access Environment. The Swedish Experience. Persson U, European Market Access University Dimploma Paris 2010
7. Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (duodopa(R)) in sweden. Willis M, Persson U, Zoellner Y, Gradl B, Appl Health Econ Health Policy 2010 8 377 386 10.2165/11531160-000000000-00000 21043539
8. Lakemedelsformansnamnden (LFN) Beslut (Decision) 0625/2006. TLV, Stockholm 2008
9. Lakemedelsformansnamnden (LFN) Beslut (Decision) 1023/2006. TLV, Stockholm 2006
10. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Persson U, Willis M, Odegaard K, Eur J Health Econ 2010 11 195 203 10.1007/s10198-009-0166-1 19639352
11. Avis de la Commission de la transparence. RISPERDALCONSTA L.P. HAS, Paris 2010
12. Risk Sharing for Reimbursement and Pricing of Drugs. Renaudin MN, ISPOR Connections 2010
13. AIFA, Oncology registries. AIFA, 2010
14. Pharmaceutical risk-sharing and conditional reimbursement in Italy. Gallo PF, Central and Eastern European Society of Technology Assessment in Health Care (CEESTAHC) 2008
15. Central and regional policies affecting drugs market access in Italy. Jommi C, Bocconi University 2010
16. Protocollo di monitoraggio dei piani di trattamento farmacologico per la malattia di Alzheimer. AIFA, Rome 2000
17. La pratica clinica mette alla prova l'innovazione terapeutica: l'esempio "ivabradina". AIFA, Rome 2008
18. Incretine: il sistema di monitoraggio dell'AIFA. AIFA, 2008
19. Criteri di valutazione per l'attribuzione del grado di innovazione terapeutica ai farmaci appartenenti a ciascuna delle tre classi della gravit della malattia bersaglio si considerano: la disponibilit di trattamenti preesistenti; l'entit dell'effetto terapeutico. AIFA, 2007
20. List of patient access schemes approved as part of a NICE appraisal. NICE, 2010
21. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? Towse A, Br J Clin Pharmacol 70 360 366
22. The 2009 Pharmaceutical Price Regulation Scheme. DoH, 2009 http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-091825
23. Trends in NHS funding: patient access schemes. Thorp H, Hughes C, Clinical Pharmacist 2010 2 319,321,322
24. Erlotinib. Non small cell lung cancer TA162. NICE, 2008
25. Lenalidomide Multiple myeloma TA171. NICE, 2009
26. Ranibizumab Acute wet macular degeneration TA155. NICE, 2008
27. Trabectedin Advanced soft tissue sarcoma TA185. NICE, 2010
28. Gefitinib Non small cell lung cancer TA192. NICE, 2010
29. Sunitinib Advanced and/or metastatic renal cell cancer TA169. NICE, 2009
30. Sunitinib Gastrointestinal stromal tumours TA179. NICE, 2009
31. Cetuximab Colorectal cancer TA176. NICE, 2009
32. Certolizumab Rheumatoid arthritis TA186. NICE, 2010
33. Ustekinumab Psoriasis TA180. NICE, 2009
34. Bortezomib Multiple myeloma TA129. NICE, 2007
35. Myelodysplastic syndromes-azacitidine TA218. NICE, 2011
36. Renal cell carcinoma (first line metastatic)-pazopanib TA215. NICE, 2011
37. Cost effective provision of disease modifying therapies for people with multiple sclerosis. DoH, London 2002
38. Design of Patient Access Schemes in the UK: Influence of Health Technology Assessment by the National Institute for Health and Clinical Excellence. Jaroslawski S, Toumi M, Appl Health Econ Health Policy 2011 9 209 215 10.2165/11592960-000000000-00000 21682349
39. Risk-sharing agreements for innovative drugs: a new solution to old problems? de Pouvourville G, Eur J Health Econ 2006 7 155 157 10.1007/s10198-006-0386-6 16912890 (Pubitemid 44581779)
40. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Towse A, Garrison LP Jr, Pharmacoeconomics 2010 28 93 102 10.2165/11314080-000000000-00000 20085386
41. Avis de la Commission de la transparence. AVANDIA. Paris: Haute Authorite de Sante 2010
42. The Pricing and Reimbursement Environment for Neurology Drugs. Grubert N, Spectrum Massachusetts 2009
43. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study - early results and lessons for the future. Pickin M, Cooper CL, Chater T, O'Hagan A, Abrams KR, Cooper NJ, Boggild M, Palace J, Ebers G, Chilcott JB, et al. BMC Neurol 2009 9 1 10.1186/1471-2377-9-1 19126193
44. A Report into the Uptake of Patient Access Schemes in the NHS. BOPA, British Oncology Pharmacy Association 2009
45. Patient access schemes for high-cost cancer medicines. Williamson S, Lancet Oncology 2010 11 111 112 10.1016/S1470-2045(09)70402-4 20152762
46. NHS drugs adviser questions price policy. Jack A, Financial Times London 2010
47. Italy to cut cost of cancer drugs. Jack A, Financial Times London 2010
48. Progetto Cronos: i risultati dello studio osservazionale. AIFA, Rome 2004